Literature DB >> 8334583

High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression.

G Baltuch1, G Shenouda, A Langleben, J G Villemure.   

Abstract

We present a case of recurrent glioma, previously treated with maximal surgery and radiation in which a high dose of tamoxifen has stabilized the tumour clinically and has resulted in it's radiologic regression. Given tamoxifen's relative lack of toxicity, it might serve as a useful adjuvant in the treatment of recurrent glioma.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8334583     DOI： 10.1017/s0317167100047788

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN： 0317-1671            Impact factor:   2.104


  10 in total

1.  The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro.

Authors:  I F Pollack; S Kawecki
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

2.  Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines.

Authors:  A M Donson; A Banerjee; F Gamboni-Robertson; J M Fleitz; N K Foreman
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

3.  Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients.

Authors:  L Mastronardi; F Puzzilli; W T Couldwell; J O Farah; P Lunardi
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

4.  Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.

Authors:  M Napolitano; F Keime-Guibert; A Monjour; C Lafitte; A Ameri; P Cornu; P Broët; J Y Delattre
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle progression.

Authors:  A Besson; V W Yong
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

6.  Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.

Authors:  Alexander M Spence; Richard A Peterson; Jeffrey D Scharnhorst; Daniel L Silbergeld; Robert C Rostomily
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

7.  High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma.

Authors:  S M Chang; F G Barker; S L Huhn; M K Nicholas; M Page; J Rabbitt; M D Prados
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

8.  Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation.

Authors:  G H Baltuch; N P Dooley; K M Rostworowski; J G Villemure; V W Yong
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

10.  Measurement of tamoxifen-induced apoptosis in glioblastoma by cytometric bead analysis of active caspase-3.

Authors:  Joy K Zartman; Nicholas K Foreman; Andrew M Donson; Julie M Fleitz
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.